Acide Éthylènediaminetétracétique, Calcium Disodium Edathamil, Calcium Disodium EDTA, Calcium Disodium Edetate, Calcium Disodium Versenate, Calcium Edetate, Calcium EDTA, Chelation Therapy, Disodium Edathamil, Disodium Edetate, Disodium EDTA, Disodium ethylenediamine tetraacetic acid, Disodium Tetraacetate, EDTA de Calcium Disodique, EDTA de Fer, Ethylenediamine tetraacetic acid, Éthylènediaminetétraacétate de Calcium et de Disodium, Éthylène-Diamine-Tétracétate Disodique, Iron EDTA, Sodium Edetate, Traitement Chélateur, Trisodium ethylenediamine tetraacetic acid.
EDTA is a prescription medicine, given by injection into the vein (intravenously) or into the muscle (intramuscularly).
Intravenous EDTA is used to treat lead poisoning and brain damage caused by lead poisoning; to evaluate a patient's response to therapy for suspected lead poisoning; to treat poisonings by radioactive materials such as plutonium, thorium, uranium, and strontium; for removing copper in patients with Wilson's disease; and for treating high levels of calcium.
EDTA is also used intravenously for heart and blood vessel conditions including irregular heartbeat due to exposure to chemicals called cardiac glycosides, “hardening of the arteries” (atherosclerosis), chest pain (angina), high blood pressure, high cholesterol, and blood circulation problems such as intermittent claudication and Raynaud's syndrome.
Other intravenous uses include treatment of cancer, rheumatoid arthritis, osteoarthritis, an eye condition called macular degeneration, diabetes, Alzheimer's disease, multiple sclerosis, Parkinson's disease, and skin conditions including scleroderma and psoriasis.
EDTA is also used intramuscularly for lead poisoning and related brain damage.
EDTA is sometimes used as an ointment for skin irritations produced by metals such as chromium, nickel, and copper.
Eye drops containing EDTA are used to treat calcium deposits in the eye.
In foods, EDTA bound to iron is used to “fortify” grain-based products such as breakfast cereals and cereal bars. EDTA is also used in calcium and sodium compounds to preserve food; and to promote the color, texture, and flavor of food.
In manufacturing, EDTA is used in calcium and sodium compounds to improve stability in pharmaceutical products, detergents, liquid soaps, shampoos, agricultural chemical sprays, oil emulsion devices, contact lens cleaners and cosmetics. It is also used in certain blood collection tubes used by medical laboratories.
How does it work?
EDTA is a chemical that binds and holds on to (chelates) minerals and metals such as chromium, iron, lead, mercury, copper, aluminum, nickel, zinc, calcium, cobalt, manganese, and magnesium. When they are bound, they can't have any effects on the body and they are removed from the body.
- Treating lead poisoning. Administering EDTA intravenously and intramuscularly is effective for treating lead poisoning and brain damage caused by lead exposure. The calcium disodium form of EDTA is approved by the U.S. Food and Drug Administration (FDA) for these uses. Treatment with calcium disodium EDTA improves symptoms of lead poisoning such as abdominal pain, fatigue, constipation, and loss of appetite. It also seems to slow progression of kidney failure in patients who have had long-term lead poisoning. However, EDTA does not seem to be effective for diagnosing lead poisoning.
Likely Effective for...
- Emergency treatment of life-threatening high calcium levels (hypercalcemia), when given intravenously. The disodium form of EDTA is approved by the FDA for this use, but healthcare providers generally prefer other methods of treatment that are less likely to cause kidney side effects.
- Treating heart rhythm problems caused by drugs such as digoxin (Lanoxin). The disodium form of EDTA is approved by the FDA for this use, but healthcare providers generally prefer other treatments such as lidocaine or phenytoin (Dilantin) because they are considered safer and more effective.
Possibly Effective for...
- Treating calcium deposits in the eye. After appropriate preparation of the eye, a single application of the disodium form of EDTA can clear calcium deposits in the eye and improve eyesight.
Possibly Ineffective for...
- Hardened skin (scleroderma).
Likely Ineffective for...
- Treating coronary heart disease (CHD).
- Treating peripheral arterial occlusive disease.
Insufficient Evidence to Rate Effectiveness for...
- Poisoning by radioactive products.
- Wilson's disease.
- Atherosclerosis (hardening of the arteries).
- High cholesterol.
- High blood pressure.
- Raynaud's syndrome.
- Vision problems.
- Alzheimer's disease.
- Multiple sclerosis.
- Parkinson's disease.
- Chest pain (angina).
- Other conditions.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
EDTA is safe when used as a prescription medicine, as eye drops, and in small amounts as a preservative in foods. EDTA can cause abdominal cramps, nausea, vomiting, diarrhea, headache, low blood pressure, skin problems, and fever.
It is UNSAFE to use more than 3 grams of EDTA per day, or to take it longer than 5 to 7 days. Too much can cause kidney damage, dangerously low calcium levels, and death.
Special Precautions & Warnings:Pregnancy and breast-feeding: EDTA seems to be safe when used in food amounts. The safety of larger amounts is unknown.
Asthma: Nebulizer solutions containing disodium EDTA as a preservative can cause the breathing tubes to narrow in some people with asthma. The size of the dose determines the amount of the narrowing.
Heart rhythm problems: EDTA might make heart rhythm problems worse.
Diabetes: EDTA might interfere with blood sugar control because it can interact with insulin.
Low calcium levels in the blood (hypocalcemia): EDTA can decrease serum calcium levels, making hypocalcemia worse.
Low potassium (hypokalemia): EDTA can bind with potassium and increase the amount of potassium that is flushed out in the urine. This might cause potassium levels to drop too low, especially in people who have low levels to begin with. If you have this problem, don't use EDTA.
Low magnesium levels in the blood (hypomagnesemia): EDTA can bind with magnesium and increase the amount of magnesium that is flushed out in the urine. This might cause magnesium levels to drop too low, especially in people who have low levels to begin with. If you have this problem, don't use EDTA.
Liver problems and hepatitis: EDTA might make liver disease worse. Avoid using EDTA if you have a liver condition.
Kidney problems: EDTA can harm the kidney and might make kidney disease worse. EDTA doses should be reduced in patients with kidney disease. Avoid using EDTA if you have severe kidney disease or kidney failure.
Seizures (epilepsy): There is some concern that EDTA might increase the risk of seizure in people with epilepsy or in people who tend to have seizures. EDTA can cause severe decreases in blood levels of calcium, and this can cause a seizure.
Tuberculosis (TB): Tuberculosis is a lung infection that is caused by particular bacteria. Sometimes the body is able to “wall off” pockets of infection, making the infection inactive. The bacteria remain alive behind the wall of scar tissue, but they can't get out to cause illness or infect other people. This scar tissue frequently contains calcium. There is some concern that EDTA might be able to bind the calcium in the scar tissue, causing the “walls” to give way and release bacteria. Don't use EDTA if you have active TB or had TB in the past.
InsulinInteraction Rating: Major Do not take this combination.
EDTA can decrease blood sugar. Insulin is also used to decrease blood sugar. Taking EDTA along with insulin can cause serious decreases in your blood sugar. Monitor your blood sugar closely. The dose of your insulin might need to be changed.
Warfarin (Coumadin)Interaction Rating: Major Do not take this combination.
Warfarin (Coumadin) is used to slow blood clotting. EDTA has been reported to decrease the effectiveness of warfarin (Coumadin). Decreasing the effectiveness of warfarin (Coumadin) might increase the risk of clotting. It is unclear why this interaction might occur. Be sure to have your blood checked regularly. The dose of your warfarin (Coumadin) might need to be changed.
Water pills (Diuretic drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Large amounts of EDTA can decrease potassium levels in the body. "Water pills" can also decrease potassium in the body. Taking EDTA along with "water pills" might decrease potassium in the body too much.
The following doses have been studied in scientific research:
APPLIED TO THE SKIN:
- For calcium deposits on the cornea of the eye: Healthcare providers use EDTA as part of a procedure.
- For lead poisoning and also for high levels of calcium in the blood: Healthcare providers give EDTA intravenously (by IV).
- For lead poisoning: Healthcare providers give EDTA in a shot (by injection).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Anderson PO, Knoben JE, Troutman WG. Handbook of Clinical Drug Data. 9th ed. Stamford, CT: Appleton & Lange, 1999.
Anon. Questions and Answers about chelation therapy. American Heart Association 2000. Available at: www.americanheart.org. (Accessed 17 November 2000).
Barnett AJ, Coventry DA. Scleroderma. 1. Clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969;1:992-1001.
Beasley R, Fishwick D, Miles JF, Hendeles L. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy 1998;18:130-9. View abstract.
Carey CF, Lee HH, Woeltje KF. The Washington Manual of Medical Therapeutics. Philadelphia, PA: Lippincott-Raven Publishers, 1998.
Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs 1996;10:78-86. View abstract.
Chappell LT, Wilson J, Ernst E. Chelation therapy for vascular disease. Circulation 1999;99:164-5.
Chappell LT. EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Altern Ther Health Med 1995;1:53-7. View abstract.
Chisolm JJ Jr. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. J Toxicol Clin Toxicol 1992;30:493-504.
Christensen K, Theilade D. Edta chelation therapy: an ethical problem. Med Hypotheses 1999;53:69-70. View abstract.
Electronic Code of Federal Regulations. Title 21. Part 182 -- Substances Generally Recognized As Safe. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=182
Elihu N, Anandasbapathy S, Frishman WH. Chealtion therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane. J Clin Pharmacol 1998;38:101-5. View abstract.
Ellsworth AJ, Witt DM, Dugdale DC, et al. Medical Drug Reference. Saint Louis, MO: Mosby-Year Book Inc 1998:302-3.
Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. Am Heart J 2000;140:139-41. View abstract.
Ernst E. Chelation therapy for peripheral arterial occlusive disease: a systematic review. Circulation 1997;96:1031-3. View abstract.
FDA, Center for Food Safety and Applied Nutrition, Office of Premarket Approval, EAFUS: A food additive database. Website: vm.cfsan.fda.gov/~dms/eafus.html (Accessed 23 February 2006).
Fuleihan FJ, Kurban AK, Abboud RT, et al. An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Br J Dermatol 1968;80:184-9.
Golan A, Savir H, Bar-Meir S, et al. Band keratopathy due to hyperparathyroidism. Ophthalmologica 1975;171:119-22. View abstract.
Gordon RA, Roberts G, Amin Z, et al. Aggressive approach in the treatment of acute lead encephalopathy with an extraordinarily high concentration of lead. Arch Pediatr Adolesc Med 1998;152:1100-4. View abstract.
Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. Pharmacotherapy 2002;22:1067-9.. View abstract.
Green S. Chelation therapy: unproven claims and unsound theories. Quackwatch 2000. Available at: http://www.quackwatch.org (Accessed 17 November 2000).
Grier MT, Meyers DG. So much writing, so little science: a review of 37 years literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27:1504-9. View abstract.
Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. J Intern Med 1992;231:261-7. View abstract.
Gundling K, Ernst E. Complementary and alternative medicine in cardiovascular disease: what is the evidence it works? WJM 1999;171:191-4.
Hardman JG, Limbird LL, Molinoff PB, eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996.
Heimbach J, Rieth S, Mohamedshah F, et al. Safety assessment of iron EDTA [sodium iron (Fe(3+) ethylenediaminetetraacetic acid]: summary of toxological fortification and exposure data. Food Chem Toxicol 2000;38:99-111. View abstract.
Keech MK, McCann DS, Boyle AJ, Pinkus H. Effect of ethylenediaminetetra-acetic acid (EDTA) and tetrahyroxyquinone on sclerodermatous skin. Histologic and chemical studies. J Invest Dermatol 1966;47:235-46.
Kidd PM. Integrative cardiac revitalization: bypass surgery, angioplasty, and chelation. Benefits, risks, and limitations. Altern Med Rev 1998;3:4-17. View abstract.
Kitchell JR, Palmon F, Aytan N, Meltzer LE. The treatment of coronary artery disease with disodium EDTA. A reappraisal. Am J Cardiology 1963;11:501-6.
Lacy CF, Armstrong LL, Ingrim NB, et al. Drug Information Handbook. 6th ed. Hudson, OH:Lexi-Comp Inc 1998:439-41.
Lamas GA, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? Am Heart J 2000;140:4-5.
Lin JL, Ho HH, Yu CC. Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial. Ann Intern Med 1999;130:7-13. View abstract.
Lyon AF, DeGraff AC. Reappraisal of digitalis. X. Treatment of digitalis toxicity. Am Heart J 1967;73:835-7.
Margolis S. Chelation therapy is ineffective for the treatment of peripheral vascular disease. Altern Ther Health Med 1995;1:53-6.
Mehbod H. Treatment of lead intoxication. Combined use of peritoneal dialysis and edetate calcium disodium. JAMA 1967;201:972-4.
Mortensen ME, Walson PD. Chelation therapy for childhood lead poisoning. The changing scene in the 1990s. Clin Pediatr (Phila) 1993;32:284-91.
Neldner KH, Winkelmann RK, Perry HO. Scleroderma An evaluation of treatment with disodium edetate. Arch Dermatol 1962;86:95-9.
Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses 1998;27:41-9. View abstract.
Popovici A, Geschickter CF, Reinovsky A, Rubin M. Experimental control of serum calcium levels in vivo. Proc Soc Exp Biol Med 1950;74:415-7.
Schubert J. Chelation in medicine. Sci Am 1966;214:40-50.
Sen BH, Akdeniz BG, Denizci AA. The effect of ethylenediamine-tetraacetic acid on Candida albicans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:651-5.. View abstract.
Shrand H. Treatment of lead poisoning with intramuscular edathamil calcium-disodium. Lancet 1961;1:310-2.
Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis. Am J Surg 1991;162:122-5. View abstract.
Soffer A. Chelation therapy for arteriosclerosis. JAMA 1975;233:1206-7. View abstract.
Surawica B. Use of the chelating agent, EDTA, in digitalis intoxication and cardiac arrhthymias. Prog Cardiovasc Dis 1960;2:432-43.
Taweechaisupapong S, Doyle RJ. Sensitivity of bacterial coaggregation to chelating agents. FEMS Immunol Med Microbiol 2000;28:343-6. View abstract.
van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. Circulation 1994;90:1194-9. View abstract.
Whittaker P, Vanderveen JE, Dinovi MJ, et al. Toxicological profile, current use, and regulatory issues on EDTA compounds for assessing use of sodium iron EDTA for food fortification. Regul Toxicol Pharmacol 1993;18:419-27.. View abstract.
Yanoff M, Duker JS. Ophthalmology. Saint Louis, MO: Mosby-Year Book Inc., 1999.
Zatlin GS, Senaldi EM, Bruckheim AH. Adult lead poisoning. Am Fam Physician 1985;32:137-43. View abstract.